Also called personalized medicine, this evolving field makes use of an individual’s genes, lifestyle, environment and other factors to identify unique disease risks and guide treatment decision-making.
Masimo's MightySat Medical is the first FDA-cleared pulse oximeter available to consumers without a prescription, which could disrupt the market for the notoriously inaccurate at-home devices.
MediView’s technologies utilize AR to provide clinicians with 3D “X-ray vision” guidance during minimally invasive procedures and surgeries, while also offering remote collaboration.
The Mayo Clinic Center for Individualized Medicine is collaborating with Helix to develop applications focused on educating consumers about their genetic data and health-related information.
The Patient-Centered Outcomes Research Institute Board of Governors has approved $9 million to fund two research studies focused on the treatment and prevention of obesity in children and adults.
Google announced the formation of a new parent company, called Alphabet, as well as plans to increase its focus on healthcare-related initiatives starting with a partnership that will develop low-cost sensors to improve diabetes management.
The vast majority of providers surveyed said they are not confident that the healthcare industry will meet the 10-year goal for nationwide interoperability set by the Office of the National Coordinator for Health IT.
The transition from volume- to value-based care is underway in the U.S., but a tremendous amount of uncertainty—and anxiety—continues to plague the providers who deliver that care.
The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.
The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks.
Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.
